Pharmaceutical NanotechnologyEnzymatic characterization of lipid-based drug delivery systems
Section snippets
Acknowledgements
VINNOVA in Sweden and Erhvervsfremme Styrelsen in Denmark are gratefully acknowledged for financial support to the Øresund contracts. Halofantrine was kindly donated by GlaxoSmithKline (West Sussex, UK).
References (10)
- et al.
Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis
J. Pharm. Biomed. Anal.
(2001) - et al.
Partitioning of halofantrine hydrochloride between water, micellar solutions, and soybean oil: effects on its apparent ionization constant
J. Pharm. Sci.
(2003) - et al.
A dynamic in vitro lipolysis model. II. Evaluation of the model
Eur. J Pharm Sci.
(2001) - et al.
Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs
Pharm. Res.
(1998) - et al.
Submicron particles of reversed lipid phases in water stabilized by a nonionic amphiphilic polymer
Langmuir
(1997)
Cited by (43)
Exploring LIPIDs for their potential to improves bioavailability of lipophilic drugs candidates: A review
2023, Saudi Pharmaceutical JournalTargeted delivery and pH-responsive release of doxorubicin to cancer cells using calcium carbonate/hyaluronate/glutamate mesoporous hollow spheres
2017, Journal of Colloid and Interface ScienceTacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement
2016, European Journal of Pharmaceutics and BiopharmaceuticsBioavailability and delivery of nutraceuticals by nanoparticles
2016, NutraceuticalsTableting lipid-based formulations for oral drug delivery: A case study with silica nanoparticle-lipid-mannitol hybrid microparticles
2013, Journal of Pharmaceutical SciencesCitation Excerpt :Therefore, in the current study, both SLH microparticles (A and E) achieved greater than 85% coumarin 102 release within 30 min under simulated sink conditions, which conforms to the US Food and Drug Administration criteria for classification as immediate-release dosage forms.25 Efforts to use standard pharmacopoeial dissolution models for in vivo correlation of Biopharmaceutics Classification System class II drug formulations have been challenging because of the complex nature of intra-luminal processes, and recent studies have established the importance of lipid digestion on the solubilisation ability of lipid-based formulations.26–28 Upon oral dosing of lipid-based delivery systems, the presence of acid-stable lipases initiates hydrolysis of triglycerides.